Policy Watch: 10 Regulatory Updates — March 20, 2026

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

This regulation schedules three synthetic opioids as controlled substances, with minimal direct relevance to cannabis medicine unless cannabis is considered as an alternative pain management option in clinical practice.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

This regulatory item addresses Schedule I placement of ethylphenidate, a controlled substance unrelated to cannabis, and has no direct relevance to cannabis medicine practice or patient care.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

This regulation temporarily schedules two synthetic opioids in Schedule I but does not directly impact cannabis clinical practice, as it addresses different controlled substances outside the cannabis regulatory framework.

Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425

Regulatory Summary DEA authorization for controlled-biopharmaceutical importation (2024-20085) establishes licensing requirements enabling qualified entities to import cannabis-derived pharmaceutical products for clinical use and patient access.

Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

This DEA action schedules synthetic opioids, not cannabis, but affects pain management alternatives available to patients currently using cannabis therapeutics for pain relief.

Schedules of Controlled Substances: Rescheduling of Marijuana

Regulatory Summary The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing medical utility and reducing prescribing restrictions for qualified healthcare providers treating patients.

Definition of Engaged in the Business as a Dealer in Firearms

This firearms regulation defines dealer licensing requirements and has no direct relevance to cannabis clinicians or patients, as it addresses federal weapons commerce rather than cannabis medical practice or treatment.

Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I

The DEA placed three synthetic opioids in Schedule I, establishing stricter controls on substances with abuse potential—relevant to cannabis clinicians managing pain patients who may encounter these controlled alternatives.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I

This regulatory action schedules three synthetic opioids in Schedule I; it is not directly relevant to cannabis clinicians or patients as it addresses different controlled substances.

Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I

Regulatory Summary The DEA placed 2-Methyl AP-237, a synthetic opioid, into Schedule I, establishing it as a controlled substance with no accepted medical use—relevant to cannabis clinicians treating patients who may use multiple controlled substances.